4.6 Article

Differential diagnosis in inflammatory bowel disease colitis: State of the art and future perspectives

期刊

WORLD JOURNAL OF GASTROENTEROLOGY
卷 21, 期 1, 页码 21-46

出版社

BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v21.i1.21

关键词

Crohn's disease; Ulcerative colitis; Inflammatory bowel disease unclassified; Advanced endoscopic imaging; Biomarkers; Histopathology

向作者/读者索取更多资源

Distinction between Crohn's disease of the colon-rectum and ulcerative colitis or inflammatory bowel disease (IBD) type unclassified can be of pivotal importance for a tailored clinical management, as each entity often involves specific therapeutic strategies and prognosis. Nonetheless, no gold standard is available and the uncertainty of diagnosis may frequently lead to misclassification or repeated examinations. Hence, we have performed a literature search to address the problem of differential diagnosis in IBD colitis, revised current and emerging diagnostic tools and refined disease classification strategies. Nowadays, the differential diagnosis is an untangled issue, and the proper diagnosis cannot be reached in up to 10% of patients presenting with IBD colitis. This topic is receiving emerging attention, as medical therapies, surgical approaches and leading prognostic outcomes require more and more disease-specific strategies in IBD patients. The optimization of standard diagnostic approaches based on clinical features, biomarkers, radiology, endoscopy and histopathology appears to provide only marginal benefits. Conversely, emerging diagnostic techniques in the field of gastrointestinal endoscopy, molecular pathology, genetics, epigenetics, metabolomics and proteomics have already shown promising results. Novel advanced endoscopic imaging techniques and biomarkers can shed new light for the differential diagnosis of IBD, better reflecting diverse disease behaviors based on specific pathogenic pathways.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Geriatrics & Gerontology

Multidimensional Prognostic Index Predicts Clinical Outcome and Mortality in Hospitalised Older Patients with Diverticular Disease

Marco Vincenzo Lenti, Nicola Aronico, Paolo Giuffrida, Stefania Costa, Martina Costetti, Clarissa Musacchio, Luca Pastorelli, Caterina Mengoli, Federica Borrelli de Andreis, Sara Cococcia, Carmine Tinelli, Catherine Klersy, Maurizio Vecchi, Alberto Pilotto, Antonio Di Sabatino

Summary: The Multidimensional Prognostic Index (MPI) can predict mortality and is associated with a higher risk of developing diverticular disease (DD) complications in older patients. Patients with higher MPI groups have a greater likelihood of developing DD complications.

GERONTOLOGY (2022)

Article Medicine, Research & Experimental

Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study

Stefano Mazza, Nicole Piazza O. Sed, Francesco Simone Conforti, Alberto Fasci, Alessandro Rimondi, Beatrice Marinoni, Valentina Casini, Chiara Ricci, Francesca Munari, Lorena Pirola, Pietro Invernizzi, Carlo Girelli, Guido Lupinacci, Luca Pastorelli, Flaminia Cavallaro, Luca Ferraris, Alice Colucci, Arnaldo Amato, Gian Eugenio Tontini, Maurizio Vecchi, Gionata Fiorino, Flavio Caprioli

Summary: A study in Italy evaluated the safety and efficacy of double-switching from originator IFX to CT-P13 and subsequently to SB2 in patients with IBD. Results showed that the double switch was associated with high continuation rates of IFX therapy and high clinical remission rates, without significant differences in safety and efficacy compared to single-switching.

CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2022)

Article Gastroenterology & Hepatology

Clinical features of type 1 and 2 refractory celiac disease: Results from a large cohort over a decade

Luca Elli, Pietro Soru, Leda Roncoroni, Francesca Gaia Rossi, Valeria Ferla, Luca Baldini, Nicoletta Nandi, Lucia Scaramella, Alice Scricciolo, Alessandro Rimondi, Nicola Fuscoi, Giorgio Alberto Croci, Umberto Gianelli, Lilla Crog, Marzia Barbierig, Vincenza Lombardob, Andrea Costantinoa, Valentina Vairaa, Stefano Ferrero, Gian Eugenio Tontini, Giulio Barigellettih, Sabrina Fabianoh, Luisa Doneda, Maurizio Vecchi

Summary: This study describes the clinical and histological features of a cohort of patients with refractory celiac disease (RCeD) at diagnosis, after therapy, and at lymphoma onset, as well as evaluates the rate and causes of death over a 17-year follow-up. The results show differences in clinical severity, response to therapy, and mortality between RCeD-I and RCeD-II, with atrophy extension being associated with disease severity and mortality.

DIGESTIVE AND LIVER DISEASE (2023)

Article Gastroenterology & Hepatology

Risk factors for inadequate bowel preparation in patients using high- and low-volume cleansing products

Vincenzo Occhipinti, Paola Soriani, Sara Vavassori, Maria Laura Annunziata, Francesco Bagolini, Flaminia Cavallaro, Pavlos Lagoussis, Valentina Milani, Emanuele Rondonotti, Luisa Spina, Maurizio Vecchi, Luca Pastorelli, Gian Eugenio Tontini

Summary: Bowel preparation is crucial for colonoscopy completeness and lesions detection. Identification of preparation-specific risk factors for inadequate bowel preparation may lead to a personalized prescription of cleansing products to refine patients' tolerance and improve endoscopic outcomes.

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2023)

Review Gastroenterology & Hepatology

Treatment options for gastrointestinal bleeding blue rubber bleb nevus syndrome: Systematic review

Alessandro Rimondi, Andrea Sorge, Alberto Murino, Nicoletta Nandi, Lucia Scaramella, Maurizio Vecchi, Gian Eugenio Tontini, Luca Elli

Summary: This study conducted a systematic review of treatment options for Blue rubber bleb nevus syndrome (BRBNS), and found that endoscopy, surgery, and systemic drug therapy are feasible choices. Compared to endoscopy and surgery, endoscopic treatment requires more sessions to achieve complete eradication, and systemic drug therapy is favored as a second-line treatment after treatment failure or recurrence, but with more reported adverse events.

DIGESTIVE ENDOSCOPY (2023)

Article Gastroenterology & Hepatology

Artificial Intelligence Enabled Histological Prediction of Remission or Activity and Clinical Outcomes in Ulcerative Colitis

Marietta Iacucci, Tommaso Lorenzo Parigi, Rocio Del Amor, Pablo Meseguer, Giulio Mandelli, Anna Bozzola, Alina Bazarova, Pradeep Bhandari, Raf Bisschops, Silvio Danese, Gert De Hertogh, Jose G. Ferraz, Martin Goetz, Enrico Grisan, Xianyong Gui, Bu Hayee, Ralf Kiesslich, Mark Lazarey, Remo Panaccione, Adolfo Parra-Blanco, Luca Pastorelli, Timo Rath, Elin S. Royset, Gian Eugenio Tontini, Michael Vieth, Davide Zardo, Subrata Ghosh, Valery Naranjo, Vincenzo Villanacci

Summary: An artificial intelligence computer-aided diagnosis system was developed and validated to evaluate UC biopsies and predict prognosis. The system showed high accuracy and sensitivity in assessing biopsy results and predicting outcomes.

GASTROENTEROLOGY (2023)

Article Medicine, General & Internal

Insights into Mesalazine Use in Clinical Practice of Young Gastroenterologists

Olga Maria Nardone, Giovanni Marasco, Loris Riccardo Lopetuso, Giammarco Mocci, Luca Pastorelli, Carlo Petruzzellis, Franco Scaldaferri

Summary: This study investigated the use of mesalazine in the clinical practice of young gastroenterologists. The results showed that there were significant differences in the use of mesalazine between non-dedicated and IBD physicians, especially in the management of moderate-severe ulcerative colitis. It was also observed that non-IBD physicians were less likely to prescribe mesalazine for colorectal cancer chemoprevention.

JOURNAL OF CLINICAL MEDICINE (2023)

Review Medicine, General & Internal

Personalize, participate, predict, and prevent: 4Ps in inflammatory bowel disease

Marco Vincenzo Lenti, Maria Lia Scribano, Livia Biancone, Rachele Ciccocioppo, Daniela Pugliese, Luca Pastorelli, Gionata Fiorino, Edoardo Savarino, Flavio Andrea Caprioli, Sandro Ardizzone, Massimo Claudio Fantini, Gian Eugenio Tontini, Ambrogio Orlando, Gianluca Matteo Sampietro, Giacomo Carlo Sturniolo, Giovanni Monteleone, Maurizio Vecchi, Anna Kohn, Marco Daperno, Renata D'Inca, Gino Roberto Corazza, Antonio Di Sabatino

Summary: IBD is a complex immune-mediated disorder affecting the gastrointestinal and systemic manifestations, leading to poor quality of life and negative health outcomes. A comprehensive management considering both biological and non-biological factors is necessary. The 4P medicine framework, including personalization, prediction, prevention, and participation is useful for tailoring interventions in IBD patients.

FRONTIERS IN MEDICINE (2023)

Article Gastroenterology & Hepatology

SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves

Cristina Bezzio, Marta Vernero, Stefania Costa, Alessandro Armuzzi, Gionata Fiorino, Sandro Ardizzone, Jenny Roselli, Sonia Carparelli, Ambrogio Orlando, Flavio Andrea Caprioli, Fabiana Castiglione, Chiara Vigano, Davide Ribaldone, Fabiana Zingone, Rita Monterubbianesi, Nicola Imperatore, Stefano Festa, Marco Daperno, Ludovica Scucchi, Antonio Ferronato, Luca Pastorelli, Eleonora Alimenti, Paola Balestrieri, Chiara Ricci, Maria Cappello, Carla Felice, Francesca Coppini, Patrizia Alvisi, Imma Di Luna, Viviana Gerardi, Angela Variola, Silvia Mazzuoli, Marco Vincenzo Lenti, Simone Saibeni

Summary: This study compared the characteristics and outcomes of inflammatory bowel disease (IBD) patients with SARS-CoV-2 infection between the two pandemic waves in Italy. The patients in the first wave were older, more likely to have ulcerative colitis and comorbidities, and resided more frequently in Northern Italy. The rates of negative outcomes, such as pneumonia, hospital admission, ventilatory support, and death, were significantly higher in the first wave compared to the second wave.

BMC GASTROENTEROLOGY (2023)

Article Gastroenterology & Hepatology

Prevalence of Disease-Related Malnutrition and Micronutrients Deficit in Patients with Inflammatory Bowel Disease: A Multicentric Cross-Sectional Study by the GSMII (Inflammatory Bowel Disease Study Group)

Chiara Vigano, Andrea Palermo, Giacomo Mulinacci, Lorena Pirola, Alessandra Losco, Gianmichele Meucci, Simone Saibeni, Luca Pastorelli, Arnaldo Amato, Mario Gatti, Claudio Cortelezzi, Antonio Di Sabatino, Daniela Morganti, Francesca Boni, Gianalberto Grasso, Giovanni Casella, Valentina Casini, Flavio Andrea Caprioli, Maurizio Vecchi, Cristina Bezzio, Irene Bergna, Franco Radaelli, Caterina Mengoli, Sara Massironi

Summary: Disease-related malnutrition (DRM) is prevalent in inflammatory bowel disease (IBD) patients, with a rate of 23% and no significant difference between Crohn's disease and ulcerative colitis. DRM is associated with higher hospitalization rate, more frequent use of systemic steroids, lower levels of hemoglobin, albumin, prealbumin, and higher levels of C-reactive protein. Low BMI, current hospitalization, and hospitalization in the previous month are significantly associated with DRM.

INFLAMMATORY BOWEL DISEASES (2023)

Article Gastroenterology & Hepatology

Clinical impact of videocapsule endoscopy and device-assisted enteroscopy in non-bleeding small bowel lesions

Matilde Topa, Nicoletta Nandi, Lucia Scaramella, Michele Puricelli, Marco Pennazio, Reena Sidhu, David S. Sanders, Gian Eugenio Tontini, Roberto Penagini, Maurizio Vecchi, Luca Elli

Summary: This study assessed the clinical impact of videocapsule endoscopy (VCE) and double-balloon enteroscopy (DBE) in patients with indications other than suspected small bowel bleeding (OSBB), and compared them to a control group of suspected small bowel bleeding (SSBB) patients. The results showed that VCE and DBE are effective and safe in patients with indications other than suspected small bowel bleeding, similar to their role in suspected small bowel bleeding patients.

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2023)

暂无数据